- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00214708
Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis?
Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis? A Cluster Randomised Controlled Trial in an East London Primary Care Trust
This randomised controlled trial tests whether screening people registering with general practices cost-effectively increases the detection of tuberculosis. The study objectives are to:
- recruit, and randomise with stratification, forty Hackney general practices to usual activity or screening for TB primarily during registration health checks (by practice nurses and GPs) and transfer-in visits for children (by health visitors)
- implement a screening programme comprising education, resources and clinical support for intervention practices using proven behaviour change strategies
- gather outcomes and costs
- build research capacity within an ELENoR Primary Care Research Team and across a Primary Care Trust.
The primary outcome is the proportion of TB cases identified in primary care. The study is powered to detect a 20% increase (from 55% to 75%) in the detection of new cases of TB in primary care with 80% power at the 5% significance level. Secondary outcomes are rates of prophylaxis for latent TB infection (LTBI), BCG immunisation, smear negative (early) TB and costs. Analyses will be by intention to treat.
Studieöversikt
Detaljerad beskrivning
To date, studies of screening for tuberculosis have used relatively weak designs. A randomised trial would give stronger evidence as to whether screening is worthwhile and therefore would be welcome. We have tested the feasibility of screening in two general practices in Hackney; our results suggest that it is simple and straightforward, that the people screened were comfortable taking part, and that screening does indeed identify people with tuberculosis.
How (or indeed whether) to screen for tuberculosis constitutes a major policy issue for inner city public health care. Our work will go some way toward answering this important question and will have local, national and international relevance. There are important benefits for those taking part. First, the project is part of a local health development scheme which encourages GPs to register refugees and asylum seekers. This means that a group of people who find it difficult to get health care will be more likely to be able to find a GP. Second, people registering with general practices who are screening will all have a brief discussion about tuberculosis when they attend a health check at the surgery. This will make people more informed about tuberculosis and help to remove the stigma that attends tuberculosis. Third, screening is likely to identify people with tuberculosis, or who need BCG vaccination to prevent tuberculosis. These people will benefit from early treatment or immunisation.
We will invite all general practices in Hackney to take part. Practices that agree will then be randomly allocated (by a computer programme) into two groups: practices who will screen and those who will carry on as usual without screening. The project researcher responsible for data collection will not know to which group the practices have been assigned. Practices allocated to the screening group will be offered a programme designed to encourage screening as part of the new patient registration checks (by practice nurses and GPs) and during children's transfer-in visits (by health visitors). The programme is founded on proven ways of helping people change how they work and includes the following: an education programme run by the primary care research team, with a local chest consultant as opinion leader; Heaf guns, Heaf heads, and tuberculin (to test for presence of TB); TB screening guidelines; regular support and advice from the local TB specialist nurse; incorporation of a TB screening template into the practice computer consulting system; and an incentive fee paid to the practices for carrying out the Heaf tests. TB identication rates for both groups will be ascertained after 25 months of screening. The cost of implementing the screening process will also be measured.
Patients / public involvment (subjects and partners):
People attending for new registration checks and children seen at transfer-in visits are the study participants. They will be informed about the study (using information sheets in various languages); they can decline to take part if they like. Public involvement in the design and execution of the study comes in three forms. First, the East London Refuge and Asylum seeker worker has contributed to the study design and will be involved throught the study. Second, the work is part of an East London Health Improvement Plan, which itself has public support. Third, the study has approval from the East London and Esssex Network of Researchers' Research Advisory Committee, which has two consumer representatives
Studietyp
Inskrivning
Kontakter och platser
Studieorter
-
-
-
London, Storbritannien, E9
- City and Hackney
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
The intervention is screening for TB in general practices which were randomised to control or intervention
Exclusion Criteria:
Practices that refused to participate could not be included. We excluded the general practice where the pilot study was undertaken
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Definerad befolkning
- Tidsperspektiv: Blivande
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Chris J Griffiths, DPhil, MB BS, Queen Mary University of London
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TB-02-04-CG
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Tuberkulos
-
University Children's Hospital BaselUniversity Hospital, Geneva; University Hospital Inselspital, Berne; Kantonsspital... och andra samarbetspartnersRekrytering
-
National Institute of Allergy and Infectious Diseases...AvslutadMycobacterium TuberculosisBrasilien
-
The University of Texas Health Science Center,...National Institute of Allergy and Infectious Diseases (NIAID)AvslutadMycobacterium TuberculosisFörenta staterna, Colombia, Mexiko
-
Johns Hopkins UniversityAvslutadMycobacterium TuberculosisFörenta staterna
-
National Institute of Allergy and Infectious Diseases...Avslutad
-
National Institute of Allergy and Infectious Diseases...Avslutad
-
Region SkaneRekryteringLatent tuberkulos | Mycobacterium Tuberculosis | Ihållande infektionSverige
-
François SpertiniUniversity of OxfordAvslutadTuberkulos | Mycobacterium Tuberculosis, skydd motSchweiz
-
Serum Institute of India Pvt. Ltd.Vakzine Projekt Management GmbHAktiv, inte rekryterandeMycobacterium Tuberculosis InfektionGabon, Kenya, Sydafrika, Tanzania, Uganda
-
Johns Hopkins UniversityUnited States Agency for International Development (USAID)Har inte rekryterat ännuTuberkulos | Tuberkulos, lung | Mycobacterium Tuberculosis | Tuberkulos, lymfkörtelUganda, Sydafrika, Moçambique, Indonesien, Zambia
Kliniska prövningar på Screening for Tuberculosis
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI)RekryteringDelirium | StamcellstransplantationskomplikationerFörenta staterna, Kanada
-
Chengdu CoenBiotech Co., LtdBeijing Friendship Hospital; Beijing Chest Hospital, Capital Medical UniversityAvslutad
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Shanghai Public Health Clinical Center; Air Force Military Medical University... och andra samarbetspartnersAvslutad
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.RekryteringLatent tuberkulosinfektionKina
-
GlaxoSmithKlineCorixa CorporationAvslutadTuberkulos (TB)Förenta staterna
-
Washington State UniversityNational Institute on Drug Abuse (NIDA)AvslutadSubstansmissbrukFörenta staterna
-
Bill & Melinda Gates Medical Research InstituteBill and Melinda Gates Foundation; Wellcome TrustRekryteringTuberkulosIndonesien, Kenya, Malawi, Moçambique, Sydafrika, Vietnam, Zambia
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Shenzhen Third People's Hospital; Wuhan Institute for Tuberculosis ControlRekryteringLatent tuberkulosinfektionKina
-
Forendo Pharma LtdRichmond Pharmacology LimitedAvslutadRelativ biotillgänglighetStorbritannien